In the past week, SNPX stock has gone up by 12.20%, with a monthly gain of 3.12% and a quarterly plunge of -23.02%. The volatility ratio for the week is 9.06%, and the volatility levels for the last 30 days are 7.64% for Synaptogenix Inc The simple moving average for the past 20 days is 9.10% for SNPX’s stock, with a -24.46% simple moving average for the past 200 days.
Is It Worth Investing in Synaptogenix Inc (NASDAQ: SNPX) Right Now?
Moreover, the 36-month beta value for SNPX is 1.44. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for SNPX is 1.29M and currently, short sellers hold a 0.62% of that float. On October 17, 2024, SNPX’s average trading volume was 29.62K shares.
SNPX) stock’s latest price update
The stock price of Synaptogenix Inc (NASDAQ: SNPX) has jumped by 10.33 compared to previous close of 3.00. Despite this, the company has seen a gain of 12.20% in its stock price over the last five trading days. prnewswire.com reported 2024-09-11 that NEW YORK, Sept. 11, 2024 /PRNewswire/ — Synaptogenix, Inc. (Nasdaq: SNPX) (“Synaptogenix” or the “Company”), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced today announced that it has entered into securities purchase agreements for a $5.0 million financing with existing investors involving the sale of 5,000 shares of its newly issued Series C convertible preferred stock (“preferred stock”), with a stated value of $1,000 per share, convertible into shares of its common stock in a registered public offering (the “Registered Offering”) and a concurrent private placement (the “Private Placement” and collectively with the Registered Offering, the “Offering”) of additional shares of Preferred Stock and unregistered common stock purchase warrants.
SNPX Trading at -0.49% from the 50-Day Moving Average
After a stumble in the market that brought SNPX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -62.28% of loss for the given period.
Volatility was left at 7.64%, however, over the last 30 days, the volatility rate increased by 9.06%, as shares surge +2.16% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -5.43% lower at present.
During the last 5 trading sessions, SNPX rose by +12.20%, which changed the moving average for the period of 200-days by -51.31% in comparison to the 20-day moving average, which settled at $3.03. In addition, Synaptogenix Inc saw -51.31% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for SNPX
Current profitability levels for the company are sitting at:
- -600.36 for the present operating margin
- 0.45 for the gross margin
The net margin for Synaptogenix Inc stands at -166.71. The total capital return value is set at -0.32. Equity return is now at value -7.85, with -5.54 for asset returns.
Currently, EBITDA for the company is -8.31 million with net debt to EBITDA at 2.95. When we switch over and look at the enterprise to sales, we see a ratio of -2007.6. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.98.
Conclusion
To wrap up, the performance of Synaptogenix Inc (SNPX) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
